{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:23:44Z","timestamp":1792121024257,"version":"4.4.0"},"reference-count":323,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jtct.2025.01.892","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:39:42Z","timestamp":1738928382000},"page":"194-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["American Society of Transplantation and Cellular Therapy Series: #8-Management and Prevention of Non-Aspergillus Molds in Hematopoietic Cell Transplantation Recipients"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8314-352X","authenticated-orcid":false,"given":"Abby P.","family":"Douglas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Lamoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2675-1529","authenticated-orcid":false,"given":"Teny M.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri Lynn","family":"Shigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa A.","family":"Papanicolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0277-3088","authenticated-orcid":false,"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-0568","authenticated-orcid":false,"given":"Sanjeet S.","family":"Dadwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0001","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0002","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3201\/eid1710.110087","article-title":"Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006","volume":"17","author":"Park","year":"2011","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.892_bib0003","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0004","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jtct.2025.01.892_bib0005","first-page":"183","author":"Bonifazi","year":"2019"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0006","doi-asserted-by":"crossref","first-page":"ofad059","DOI":"10.1093\/ofid\/ofad059","article-title":"Invasive Scedosporium and Lomentospora prolificans infections in Australia: a multicenter retrospective cohort study","volume":"10","author":"Neoh","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0007","first-page":"155","article-title":"Cutaneous mucormycosis","volume":"11","author":"Skiada","year":"2013","journal-title":"Skinmed"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0008","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/eci.12467","article-title":"Healthcare-associated outbreaks due to Mucorales and other uncommon fungi","volume":"45","author":"Davoudi","year":"2015","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0009","article-title":"Outbreaks of fungal infections in hospitals: epidemiology, detection, and management","volume":"9","author":"Douglas","year":"2023","journal-title":"J Fungi (Basel)"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.mycmed.2018.02.014","article-title":"Mucormycosis in Iran: a six-year retrospective experience","volume":"28","author":"Dolatabadi","year":"2018","journal-title":"J Mycol Med"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0011","doi-asserted-by":"crossref","first-page":"490.e1","DOI":"10.1016\/j.cmi.2014.12.021","article-title":"Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality","volume":"21","author":"Slavin","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0012","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/MD.0000000000000008","article-title":"Fusarium infection: report of 26 cases and review of 97 cases from the literature","volume":"92","author":"Muhammed","year":"2013","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0013","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0014","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/mmy\/myz060","article-title":"A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis","volume":"58","author":"Fernandez-Cruz","year":"2020","journal-title":"Med Mycol"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/jac\/dkad377","article-title":"Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes","volume":"79","author":"Matsuo","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0016","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/jof7080588","article-title":"Epidemiology of invasive fungal diseases in patients with hematologic malignancies and hematopoietic cell transplantation recipients managed with an antifungal diagnostic driven approach","volume":"7","author":"Bergamasco","year":"2021","journal-title":"J Fungi (Basel)"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0017","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/1469-0691.12002","article-title":"Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil","volume":"19","author":"Nucci","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0018","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/cid\/ciu947","article-title":"Risk factors for invasive fusariosis in patients with acute myeloid leukemia and in hematopoietic cell transplant recipients","volume":"60","author":"Garnica","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1040841X.2018.1514366","article-title":"Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope(R)","volume":"45","author":"Seidel","year":"2019","journal-title":"Crit Rev Microbiol"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0020","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbmt.2014.03.004","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"20","author":"Girmenia","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.892_bib0021","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1086\/522189","article-title":"Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study\u2014Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne","volume":"45","author":"Pagano","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0022","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/jof7100848","article-title":"Changing epidemiology of invasive fungal disease in allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Puerta-Alcalde","year":"2021","journal-title":"J Fungi (Basel)"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0023","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/mmy\/myv018","article-title":"Phaeohyphomycosis in transplant recipients: results from the Transplant Associated Infection Surveillance Network (TRANSNET)","volume":"53","author":"McCarty","year":"2015","journal-title":"Med Mycol"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0024","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1399-3062.2008.00327.x","article-title":"Transplant-associated Ochroconis gallopava infections","volume":"10","author":"Shoham","year":"2008","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0025","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMra1216008","article-title":"Mold infections of the central nervous system","volume":"371","author":"McCarthy","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0026","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cmi.2016.01.011","article-title":"Emerging infections caused by non-Aspergillus filamentous fungi","volume":"22","author":"Douglas","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0027","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/cid\/cix130","article-title":"Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis","volume":"64","author":"Lamoth","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0028","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jinf.2023.05.005","article-title":"Breakthrough invasive fungal infection among patients with haematologic malignancies: a national, prospective, and multicentre study","volume":"87","author":"Puerta-Alcalde","year":"2023","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0029","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/14737159.2024.2326474","article-title":"PCR diagnostic platforms for non-Aspergillus mold infections: ready for routine implementation in the clinic?","volume":"24","author":"Lamoth","year":"2024","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0030","first-page":"156","article-title":"Emerging mould infections: get prepared to meet unexpected fungi in your patient","volume":"58","author":"Delliere","year":"2020","journal-title":"Med Mycol"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0031","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.idc.2021.03.014","article-title":"Emerging fungal infections","volume":"35","author":"Spallone","year":"2021","journal-title":"Infect Dis Clin North Am"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0032","doi-asserted-by":"crossref","first-page":"E396","DOI":"10.1111\/j.1469-0691.2012.03908.x","article-title":"Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008)","volume":"18","author":"Xhaard","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0033","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1086\/591969","article-title":"Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation","volume":"47","author":"Garcia-Vidal","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0034","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.892_bib0035","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1056\/NEJM200402263500923","article-title":"Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants","volume":"350","author":"Marty","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0036","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1705754","article-title":"Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole","volume":"40","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0037","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cmi.2023.03.008","article-title":"COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases","volume":"29","author":"Ozbek","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0038","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.cmi.2021.10.008","article-title":"The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis","volume":"28","author":"Chuleerarux","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0039","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2017.07.025","article-title":"Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring","volume":"23","author":"Yong","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.01.892_bib0040","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis","volume":"54","author":"Petrikkos","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0041","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/cid\/cis195","article-title":"Mucormycosis in organ and stem cell transplant recipients","volume":"54","author":"Lanternier","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11046-006-0025-x","article-title":"Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients","volume":"162","author":"Bhatti","year":"2006","journal-title":"Mycopathologia"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0043","doi-asserted-by":"crossref","first-page":"ofaa646","DOI":"10.1093\/ofid\/ofaa646","article-title":"Mucormycosis in hematopoietic cell transplant recipients and in patients with hematological malignancies in the era of new antifungal agents","volume":"8","author":"Miller","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0044","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/313803","article-title":"Zygomycosis in the 1990s in a tertiary-care cancer center","volume":"30","author":"Kontoyiannis","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.01.892_bib0045","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1093\/cid\/cir869","article-title":"Host defenses against zygomycetes","volume":"54","author":"Roilides","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0046","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jinf.2009.06.002","article-title":"A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response","volume":"59","author":"Ben-Ami","year":"2009","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0047","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0039-6257(05)80041-4","article-title":"Survival factors in rhino-orbital-cerebral mucormycosis","volume":"39","author":"Yohai","year":"1994","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0048","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/jof5030059","article-title":"Mucormycosis of the central nervous system","volume":"5","author":"Chikley","year":"2019","journal-title":"J Fungi (Basel)"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0049","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.bmt.1701885","article-title":"Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis","volume":"24","author":"Maertens","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.892_bib0050","doi-asserted-by":"crossref","first-page":"e01161","DOI":"10.14309\/crj.0000000000001161","article-title":"Invasive gastrointestinal mucormycosis","volume":"10","author":"Zhong","year":"2023","journal-title":"ACG Case Rep J"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2025.01.892_bib0051","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/jac\/dkx030","article-title":"Early diagnosis of invasive mould infections and disease","volume":"72","author":"Lamoth","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0052","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1182\/blood-2011-03-316430","article-title":"How I treat mucormycosis","volume":"118","author":"Kontoyiannis","year":"2011","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.01.892_bib0053","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1093\/cid\/cir868","article-title":"Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis)","volume":"54","author":"Walsh","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0054","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.892_bib0055","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/cid\/cir122","article-title":"The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts","volume":"52","author":"Georgiadou","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0056","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/cid\/ciab1066","article-title":"Evaluation of serum Mucorales polymerase chain reaction (PCR) for the diagnosis of mucormycoses: the MODIMUCOR prospective trial","volume":"75","author":"Millon","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0057","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03585-23","article-title":"Agreement between two real-time commercial PCR kits and an in-house real-time PCR for diagnosis of mucormycosis","volume":"12","author":"Rafanomezantsoa","year":"2024","journal-title":"Microbiol Spectr"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0058","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/jiad255","article-title":"Serial quantitation of plasma microbial cell-free DNA before and after diagnosis of pulmonary invasive mold infections after hematopoietic cell transplant","volume":"229","author":"Heldman","year":"2024","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0059","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/jof10100727","article-title":"Recent advances in diagnostic approaches for mucormycosis","volume":"10","author":"Safiia","year":"2024","journal-title":"J Fungi (Basel)"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.892_bib0060","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0061","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1179\/joc.2009.21.3.322","article-title":"Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology)","volume":"21","author":"Pagano","year":"2009","journal-title":"J Chemother"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0062","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/13693780903311944","article-title":"Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases","volume":"48","author":"Shoham","year":"2010","journal-title":"Med Mycol"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0063","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jac\/dkp430","article-title":"Forty-one recent cases of invasive zygomycosis from a global clinical registry","volume":"65","author":"Ruping","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0064","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1128\/AAC.01488-07","article-title":"Comparison of lipid amphotericin B preparations in treating murine zygomycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0065","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0066","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0067","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/myc.12777","article-title":"Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species","volume":"61","author":"Marty","year":"2018","journal-title":"Mycoses"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0068","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","author":"van Burik","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0069","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.01458-07","article-title":"Combination echinocandin-polyene treatment of murine mucormycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0070","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.49.2.830-832.2005","article-title":"Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice","volume":"49","author":"Spellberg","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 3","key":"10.1016\/j.jtct.2025.01.892_bib0071","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/myc.12247","article-title":"Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia","volume":"57","author":"Klimko","year":"2014","journal-title":"Mycoses"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0072","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.892_bib0073","doi-asserted-by":"crossref","first-page":"811.e1","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0074","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0075","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.tripleo.2009.11.012","article-title":"Successful treatment of periodontal mucormycosis: report of a case and literature review","volume":"109","author":"McDermott","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0076","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0003-4975(94)90243-7","article-title":"Pulmonary mucormycosis: results of medical and surgical therapy","volume":"57","author":"Tedder","year":"1994","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0077","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/01676830.2021.1990351","article-title":"Transcutaneous retrobulbar injection of amphotericin B in rhino-orbital-cerebral mucormycosis: a review","volume":"41","author":"Nair","year":"2022","journal-title":"Orbit"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0078","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3928\/1542-8877-19960801-10","article-title":"Intraconal amphotericin B for the treatment of rhino-orbital mucormycosis","volume":"27","author":"Luna","year":"1996","journal-title":"Ophthalmic Surg Lasers"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0079","doi-asserted-by":"crossref","DOI":"10.1136\/tsaco-2019-000434","article-title":"Use of adjuvant hyperbaric oxygen therapy in a patient with traumatic inoculation of mucormycosis resulting in extremity amputation","volume":"5","author":"Kruse","year":"2020","journal-title":"Trauma Surg Acute Care Open"},{"key":"10.1016\/j.jtct.2025.01.892_bib0080","doi-asserted-by":"crossref","first-page":"101010","DOI":"10.1016\/j.lanepe.2024.101010","article-title":"Epidemiology and prognostic factors of mucormycosis in France (2012\u20132022): a cross-sectional study nested in a prospective surveillance programme","volume":"45","author":"Gouzien","year":"2024","journal-title":"Lancet Reg Health \u2013 Eur"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0081","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/jof7030217","article-title":"Breakthrough mucormycosis developing on Mucorales-active antifungals portrays a poor prognosis in patients with hematologic cancer","volume":"7","author":"Axell-House","year":"2021","journal-title":"J Fungi (Basel)"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0082","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jinf.2010.01.010","article-title":"Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009","volume":"60","author":"Campo","year":"2010","journal-title":"J Infect"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0083","doi-asserted-by":"crossref","first-page":"1105.e1","DOI":"10.1016\/j.cmi.2018.05.006","article-title":"Invasive mould disease in haematologic patients: comparison between fusariosis and aspergillosis","volume":"24","author":"Nucci","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0084","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/342328","article-title":"Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management","volume":"35","author":"Nucci","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0085","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/1469-0691.12409","article-title":"Improvement in the outcome of invasive fusariosis in the last decade","volume":"20","author":"Nucci","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0086","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3201\/eid1910.120847","article-title":"Increased incidence of invasive fusariosis with cutaneous portal of entry, Brazil","volume":"19","author":"Nucci","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0087","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2214\/AJR.07.3278","article-title":"Imaging of pulmonary fusariosis in patients with hematologic malignancies","volume":"190","author":"Marom","year":"2008","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0088","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00159-22","article-title":"Invasive fusariosis","volume":"36","author":"Nucci","year":"2023","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0089","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.11510","article-title":"Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection","volume":"98","author":"Nucci","year":"2003","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0090","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myad061","article-title":"Performance of the beta-glucan test for the diagnosis of invasive fusariosis and scedosporiosis: a meta-analysis","volume":"61","author":"Lamoth","year":"2023","journal-title":"Med Mycol"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0091","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/myc.12918","article-title":"Performance of 1,3-beta-D-glucan in the diagnosis and monitoring of invasive fusariosis","volume":"62","author":"Nucci","year":"2019","journal-title":"Mycoses"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.892_bib0092","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myac049","article-title":"Detection of circulating DNA for the diagnosis of invasive fusariosis: retrospective analysis of 15 proven cases","volume":"60","author":"Delliere","year":"2022","journal-title":"Med Mycol"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0093","doi-asserted-by":"crossref","first-page":"e87784","DOI":"10.1371\/journal.pone.0087784","article-title":"Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing","volume":"9","author":"Nucci","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0094","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/cid\/ciad520","article-title":"Emerging roles of (1\u2013>3)-beta-D-glucan in cerebrospinal fluid for detection and therapeutic monitoring of invasive fungal diseases of the central nervous system","volume":"78","author":"Walsh","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.892_bib0095","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01032-22","article-title":"A practical workflow for the identification of Aspergillus, Fusarium, Mucorales by MALDI-TOF MS: database, medium, and incubation optimization","volume":"60","author":"Barker","year":"2022","journal-title":"J Clin Microbiol"},{"issue":"suppl 3","key":"10.1016\/j.jtct.2025.01.892_bib0096","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12465","article-title":"ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others","volume":"20","author":"Tortorano","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0097","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/jac\/dkaa516","article-title":"Do high MICs predict the outcome in invasive fusariosis?","volume":"76","author":"Nucci","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0098","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1086\/503425","article-title":"Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0099","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijantimicag.2007.09.005","article-title":"In vitro interactions of antifungal agents against clinical isolates of Fusarium spp","volume":"31","author":"Cordoba","year":"2008","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0100","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s10156-013-0594-9","article-title":"Combination therapy of voriconazole and terbinafine for disseminated fusariosis: case report and literature review","volume":"19","author":"Inano","year":"2013","journal-title":"J Infect Chemother"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0101","first-page":"872","article-title":"Combination antifungal therapy for disseminated fusariosis in immunocompromised patients: a case report and literature review","volume":"49","author":"Liu","year":"2011","journal-title":"Med Mycol"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0102","doi-asserted-by":"crossref","first-page":"ofae068","DOI":"10.1093\/ofid\/ofae068","article-title":"Adjunct terbinafine in patients with leukemia and invasive fusariosis with skin lesions: discordance between responses of skin lesions and systemic outcomes","volume":"11","author":"Matsuo","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0103","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dkn215","article-title":"Combined therapy in treatment of murine infection by Fusarium solani","volume":"62","author":"Ruiz-Cendoya","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0104","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1128\/AAC.01606-08","article-title":"Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum","volume":"53","author":"Ruiz-Cendoya","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11046-010-9364-8","article-title":"Combined therapy against murine-disseminated infection by Fusarium verticillioides","volume":"171","author":"Ruiz-Cendoya","year":"2011","journal-title":"Mycopathologia"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0106","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ijantimicag.2018.08.005","article-title":"Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy","volume":"52","author":"Jenks","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0107","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1128\/AAC.46.7.2219-2228.2002","article-title":"Physiologically based pharmacokinetic model for terbinafine in rats and humans","volume":"46","author":"Hosseini-Yeganeh","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0108","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/BF01690877","article-title":"Successful treatment of catheter-related fusarial infection in immunocompromised children","volume":"14","author":"Velasco","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0109","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/cid\/ciad768","article-title":"Good outcomes in salvage therapy of fusariosis in patients with leukemia: is it the host or the drug?","volume":"79","author":"Matsuo","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0110","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/1469-0691.12409","article-title":"Improvement in the outcome of invasive fusariosis in the last decade","volume":"20","author":"Nucci","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.892_bib0111","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s10096-014-2111-1","article-title":"European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe","volume":"33","author":"Tortorano","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0112","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1396-0296.2004.04056.x","article-title":"Subcutaneous fungal infections","volume":"17","author":"Pang","year":"2004","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jtct.2025.01.892_bib0113","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12879-016-1372-y","article-title":"Lomentospora prolificans endocarditis\u2014case report and literature review","volume":"16","author":"Kelly","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"50","key":"10.1016\/j.jtct.2025.01.892_bib0114","doi-asserted-by":"crossref","first-page":"e2078","DOI":"10.1097\/MD.0000000000002078","article-title":"Osteoarticular infections caused by non-Aspergillus filamentous fungi in adult and pediatric patients: a systematic review","volume":"94","author":"Taj-Aldeen","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0115","doi-asserted-by":"crossref","first-page":"E271","DOI":"10.1111\/1469-0691.12110","article-title":"Efficacy of DNA amplification in tissue biopsy samples to improve the detection of invasive fungal disease","volume":"19","author":"Buitrago","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0116","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1128\/JCM.01862-06","article-title":"Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens","volume":"45","author":"Lau","year":"2007","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0117","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/14737159.2019.1574572","article-title":"The expanding use of matrix-assisted laser desorption\/ionization-time of flight mass spectroscopy in the diagnosis of patients with mycotic diseases","volume":"19","author":"Walsh","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"issue":"suppl 2","key":"10.1016\/j.jtct.2025.01.892_bib0118","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1093\/cid\/ciaa1943","article-title":"Assessment of the role of 1,3-beta-d-glucan testing for the diagnosis of invasive fungal infections in adults","volume":"72","author":"Lamoth","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0119","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1128\/AAC.01388-07","article-title":"Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients","volume":"52","author":"Troke","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1086\/426445","article-title":"Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome","volume":"40","author":"Husain","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0121","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/13693780902738006","article-title":"Host immune response against Scedosporium species","volume":"47","author":"Roilides","year":"2009","journal-title":"Med Mycol"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0122","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.50.3.917-921.2006","article-title":"Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi","volume":"50","author":"Cuenca-Estrella","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0123","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/AAC.46.1.62-68.2002","article-title":"In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates","volume":"46","author":"Meletiadis","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.892_bib0124","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1086\/509579","article-title":"Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006","volume":"43","author":"Lamaris","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0125","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/AAC.01160-07","article-title":"In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans","volume":"52","author":"Cuenca-Estrella","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0126","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1128\/AAC.47.1.106-117.2003","article-title":"In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates","volume":"47","author":"Meletiadis","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0127","doi-asserted-by":"crossref","first-page":"784.e1","DOI":"10.1016\/j.cmi.2020.01.012","article-title":"Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope(R) registry 2008-2019","volume":"26","author":"Jenks","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/cid\/ciaa035","article-title":"Clinical impact of metagenomic next-generation sequencing of plasma cell-free DNA for the diagnosis of infectious diseases: a multicenter retrospective cohort study","volume":"72","author":"Hogan","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0129","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01244-19","article-title":"Therapeutic challenges of non-Aspergillus invasive mold infections in immunosuppressed patients","volume":"63","author":"Lamoth","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/jof7010017","article-title":"Role and interpretation of antifungal susceptibility testing for the management of invasive fungal infections","volume":"7","author":"Lamoth","year":"2020","journal-title":"J Fungi (Basel)"},{"issue":"suppl 3","key":"10.1016\/j.jtct.2025.01.892_bib0131","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/1469-0691.12515","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi","volume":"20","author":"Chowdhary","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0132","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/jof9030283","article-title":"Phaeohyphomycosis in solid organ transplant recipients: a case series and narrative review of the literature","volume":"9","author":"Lo Porto","year":"2023","journal-title":"J Fungi (Basel)"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0133","doi-asserted-by":"crossref","first-page":"e13819","DOI":"10.1111\/tid.13819","article-title":"Dematiaceous fungal infections in solid organ transplantation: systematic review and Bayesian meta-analysis","volume":"24","author":"Radcliffe","year":"2022","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0134","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/myc.13169","article-title":"Sarocladium and Acremonium infections: new faces of an old opportunistic fungus","volume":"63","author":"Perez-Cantero","year":"2020","journal-title":"Mycoses"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0135","first-page":"145","article-title":"Current knowledge on the etiology and epidemiology of Scopulariopsis infections","volume":"58","author":"Perez-Cantero","year":"2020","journal-title":"Med Mycol"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0136","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jac\/dkaa481","article-title":"Characterization and outcome of invasive infections due to Paecilomyces variotii: analysis of patients from the FungiScope(R) registry and literature reports","volume":"76","author":"Sprute","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0137","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/jac\/dkab039","article-title":"Invasive infections with Purpureocillium lilacinum: clinical characteristics and outcome of 101 cases from FungiScope(R) and the literature","volume":"76","author":"Sprute","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0138","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/myc.13039","article-title":"Risk factors and mortality in invasive Rasamsonia spp. infection: analysis of cases in the FungiScope(R) registry and from the literature","volume":"63","author":"Stemler","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.jtct.2025.01.892_bib0139","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mmcr.2021.03.008","article-title":"Invasive Hormographiella aspergillata infection in patients with acute myeloid leukemia: report of two cases successfully treated and review of the literature","volume":"32","author":"Tschopp","year":"2021","journal-title":"Med Mycol Case Rep"},{"key":"10.1016\/j.jtct.2025.01.892_bib0140","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12879-015-0855-6","article-title":"Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"15","author":"Bow","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0141","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"issue":"suppl 7","key":"10.1016\/j.jtct.2025.01.892_bib0142","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/imj.15592","article-title":"Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology\/oncology setting, 2021","volume":"51","author":"Bupha-Intr","year":"2021","journal-title":"Intern Med J"},{"issue":"30","key":"10.1016\/j.jtct.2025.01.892_bib0143","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0144","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jtct.2020.10.003","article-title":"American Society of Transplantation and Cellular Therapy Series, 2: management and prevention of aspergillosis in hematopoietic cell transplantation recipients","volume":"27","author":"Dadwal","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0145","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/myc.12167","article-title":"Our recommendations for avoiding exposure to fungi outside the hospital for patients with haematological cancers","volume":"57","author":"Ariza-Heredia","year":"2014","journal-title":"Mycoses"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0146","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0147","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1086\/503844","article-title":"Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies","volume":"42","author":"Sipsas","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0148","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/cid\/ciz1195","article-title":"How long do we need to treat an invasive mold disease in hematology patients? factors influencing duration of therapy and future questions","volume":"71","author":"Fernandez-Cruz","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"13","key":"10.1016\/j.jtct.2025.01.892_bib0149","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1200\/JCO.2003.01.144","article-title":"Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response","volume":"21","author":"Erasmus","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0150","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cncr.22738","article-title":"Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications","volume":"110","author":"Miceli","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0151","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/QCO.0000000000000937","article-title":"Radiology-based diagnosis of fungal pulmonary infections in high-risk hematology patients: are we making progress?","volume":"36","author":"Lewis","year":"2023","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0152","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.semnuclmed.2022.07.003","article-title":"Imaging of invasive fungal infections\u2014the role of PET\/CT","volume":"53","author":"Ankrah","year":"2023","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0153","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00259-018-4062-8","article-title":"FDG PET\/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging","volume":"46","author":"Douglas","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.892_bib0154","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection-position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology","volume":"62","author":"Cornely","year":"2019","journal-title":"Mycoses"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0155","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/cid\/ciy473","article-title":"Breakthrough invasive mold infections in the hematology patient: current concepts and future directions","volume":"67","author":"Lionakis","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"24","key":"10.1016\/j.jtct.2025.01.892_bib0156","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood.2020005884","article-title":"How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease","volume":"136","author":"Puerta-Alcalde","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0157","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/myc.12901","article-title":"Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis?","volume":"62","author":"Nucci","year":"2019","journal-title":"Mycoses"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0158","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/bmt.2012.89","article-title":"The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis","volume":"48","author":"Georgiadou","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0159","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood-2002-01-0048","article-title":"A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies","volume":"100","author":"Couban","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0160","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/AAC.04435-14","article-title":"Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales","volume":"59","author":"Espinel-Ingroff","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0161","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.02456-15","article-title":"International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for Fusarium species identified by molecular methods for the CLSI broth microdilution method","volume":"60","author":"Espinel-Ingroff","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0162","first-page":"1118","article-title":"Voriconazole MICs are predictive for the outcome of experimental disseminated scedosporiosis","volume":"72","author":"Martin-Vicente","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0163","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.diagmicrobio.2018.05.019","article-title":"Lack of correlation of ECV and outcome in an in vivo murine model of systemic fusariosis","volume":"92","author":"Navarro-Rodriguez","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.892_bib0164","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1128\/AAC.01026-09","article-title":"Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection","volume":"53","author":"Rodriguez","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0165","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1128\/AAC.01463-09","article-title":"Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice","volume":"54","author":"Rodriguez","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0166","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1128\/AAC.05956-11","article-title":"In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole","volume":"56","author":"Salas","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0167","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/JCM.00318-16","article-title":"Role of antifungal susceptibility testing in non-Aspergillus invasive mold infections","volume":"54","author":"Lamoth","year":"2016","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0168","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/516480","article-title":"Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation","volume":"175","author":"Wald","year":"1997","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0169","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jpids\/pit080","article-title":"Invasive fusariosis: a single pediatric center 15-year experience","volume":"4","author":"Schwartz","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0297590","article-title":"Mucormycosis in children with cancer and hematopoietic cell transplant\u2014a single center cohort study","volume":"19","author":"Maron","year":"2024","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0171","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1097\/INF.0000000000003780","article-title":"An update on the diagnosis and treatment of invasive mold disease of the central nervous system in children","volume":"42","author":"Pana","year":"2023","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0172","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s12879-016-2005-1","article-title":"Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries","volume":"16","author":"Pana","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0173","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/bmt.2015.263","article-title":"Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis","volume":"51","author":"Riches","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0174","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00431-007-0527-7","article-title":"Fungal infections in primary immunodeficiencies","volume":"166","author":"Antachopoulos","year":"2007","journal-title":"Eur J Pediatr"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0175","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0176","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0177","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1309\/AJCPEMVYT88AVFKG","article-title":"Positive impact of fungal histopathology on immunocompromised pediatric patients with histology-proven invasive fungal infection","volume":"144","author":"Dekio","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0178","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/cid\/ciw592","article-title":"Galactomannan, beta-D-glucan, and polymerase chain reaction-based assays for the diagnosis of invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"63","author":"Lehrnbecher","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"suppl 7","key":"10.1016\/j.jtct.2025.01.892_bib0179","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1469-0691.12040","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp","volume":"18","author":"Hope","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.892_bib0180","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cmi.2019.05.019","article-title":"ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children","volume":"25","author":"Warris","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0181","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01477-16","article-title":"Safety, tolerability, and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients","volume":"61","author":"Seibel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2025.01.892_bib0182","unstructured":"European Medicines Agency 2020. Cresemba, INN-Isavuconazole. EPAR productive information. Accessed 21 Feb 2025. [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cresemba-epar-productinformation_ en.pdf]"},{"key":"10.1016\/j.jtct.2025.01.892_bib0183","unstructured":"U.S. Food and Drug Administration 2023. Drugs@FDA: FDA-Approved Drugs- Cresemba. Accessed 20 February 2025. [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/207500s015,207501s 013lbl.pdf]"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0184","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00290-21","article-title":"Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients","volume":"65","author":"Arrieta","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.892_bib0185","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00484-24","article-title":"Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial","volume":"68","author":"Segers","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0186","doi-asserted-by":"crossref","first-page":"ofae133","DOI":"10.1093\/ofid\/ofae133","article-title":"The burden of invasive fungal disease following chimeric antigen receptor T-cell therapy and strategies for prevention","volume":"11","author":"Little","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0187","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1016\/S1473-3099(23)00563-7","article-title":"Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature","volume":"24","author":"Cheok","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0188","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0189","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0190","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(20)30376-8","article-title":"Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?","volume":"8","author":"Gudiol","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0191","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 7","key":"10.1016\/j.jtct.2025.01.892_bib0192","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/imj.15588","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021","volume":"51","author":"Teh","year":"2021","journal-title":"Intern Med J"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0193","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0194","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/cid\/ciaa031","article-title":"Chimeric antigen receptor T-cell immunotherapy and need for prophylaxis for invasive mold infections","volume":"71","author":"Lewis","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0195","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.chest.2023.06.039","article-title":"Improving diagnosis of pulmonary mucormycosis: leads from a contemporary national study of 114 cases","volume":"164","author":"Coste","year":"2023","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.892_bib0196","doi-asserted-by":"crossref","first-page":"810.e1","DOI":"10.1016\/j.cmi.2015.12.006","article-title":"Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF)","volume":"22","author":"Millon","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0197","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1093\/cid\/cit094","article-title":"Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients","volume":"56","author":"Millon","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0198","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/jof5040113","article-title":"Serial detection of circulating Mucorales DNA in invasive mucormycosis: a retrospective multicenter evaluation","volume":"5","author":"Mercier","year":"2019","journal-title":"J Fungi (Basel)"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0199","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jinf.2020.05.051","article-title":"Evaluation of MucorGenius(R) Mucorales PCR assay for the diagnosis of pulmonary mucormycosis","volume":"81","author":"Guegan","year":"2020","journal-title":"J Infect"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0200","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00289-18","article-title":"Quantitative PCR (qPCR) detection of Mucorales DNA in bronchoalveolar lavage fluid to diagnose pulmonary mucormycosis","volume":"56","author":"Scherer","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jtct.2025.01.892_bib0201","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.2147\/IDR.S393201","article-title":"Metagenomic next-generation sequencing for diagnostically challenging mucormycosis in patients with hematological malignancies","volume":"15","author":"Zhang","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0202","doi-asserted-by":"crossref","first-page":"ofae425","DOI":"10.1093\/ofid\/ofae425","article-title":"Clinical utility of plasma microbial cell-free DNA sequencing among immunocompromised patients with pneumonia","volume":"11","author":"Madut","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0203","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/cid\/ciad599","article-title":"Plasma microbial cell-free DNA sequencing in immunocompromised patients with pneumonia: a prospective observational study","volume":"78","author":"Bergin","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0204","doi-asserted-by":"crossref","first-page":"e3876","DOI":"10.1093\/cid\/ciaa1639","article-title":"Liquid biopsy for invasive mold infections in hematopoietic cell transplant recipients with pneumonia through next-generation sequencing of microbial cell-free DNA in plasma","volume":"73","author":"Hill","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2025.01.892_bib0205","first-page":"1","article-title":"Diagnosis and management of invasive fungal diseases by next-generation sequencing: are we there yet?","author":"Babady","year":"2024","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0206","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/cid\/ciab1070","article-title":"Investigational antifungal agents for invasive mycoses: a clinical perspective","volume":"75","author":"Lamoth","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0207","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/jof7060451","article-title":"Reinforcing the immunocompromised host defense against fungi: progress beyond the current state of the art","volume":"7","author":"Karavalakis","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.jtct.2025.01.892_bib0208","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018202","article-title":"Checkpoint inhibitors as immunotherapy for fungal infections: promises, challenges, and unanswered questions","volume":"13","author":"Wurster","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0209","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/02681219680000101","article-title":"Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae","volume":"34","author":"Roilides","year":"1996","journal-title":"J Med Vet Mycol"},{"issue":"45","key":"10.1016\/j.jtct.2025.01.892_bib0210","doi-asserted-by":"crossref","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jtct.2025.01.892_bib0211","series-title":"Presented at: 31st European Congress of Clinical Microbiology and Infectious Diseases; 9\u201312 July 2021 (online). Abstract 01077","article-title":"Tissue distribution of (14C)-olorofim following intravenous dosing in the rat","author":"Cornelissen","year":"2021"},{"issue":"suppl_2","key":"10.1016\/j.jtct.2025.01.892_bib0212","volume":"9","author":"Maertens","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0213","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00487-18","article-title":"EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs","volume":"62","author":"Jorgensen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0214","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1093\/jac\/dkae267","article-title":"In vitro activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020-2023","volume":"79","author":"Halliday","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jtct.2025.01.892_bib0215","series-title":"Presented at: 31st European Congress of Clinical Microbiology and Infectious Diseases; 9-12 July 2021 (online). ePoster 4049","article-title":"Treatment of Scedosporium mycetoma refractory to voriconazole with olorofim","author":"Walsh","year":"2021"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0216","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jac\/dkz022","article-title":"In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies","volume":"74","author":"Rivero-Menendez","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0217","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01735-19","article-title":"Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis","volume":"64","author":"Alkhazraji","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0218","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02343-20","article-title":"Manogepix, the active moiety of the investigational agent fosmanogepix, demonstrates in vitro activity against members of the Fusarium oxysporum and Fusarium solani species complexes","volume":"65","author":"Badali","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0219","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01623-22","article-title":"Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers","volume":"67","author":"Hodges","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0220","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01795-20","article-title":"Efficacy and pharmacokinetics of fosmanogepix (APX001) in the treatment of Candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits","volume":"65","author":"Petraitiene","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0221","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/cid\/ciad570","article-title":"Update on outbreak of fungal meningitis among US residents who received epidural anesthesia at two clinics in Matamoros, Mexico","volume":"78","author":"Smith","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0222","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/cid\/ciad309","article-title":"Fosmanogepix therapy of disseminated Fusarium infection","volume":"77","author":"Winston","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0223","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/jof6020066","article-title":"Encochleated amphotericin B: is the oral availability of amphotericin B finally reached?","volume":"6","author":"Aigner","year":"2020","journal-title":"J Fungi (Basel)"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0224","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijpharm.2017.03.019","article-title":"Nanoparticles as safe and effective delivery systems of antifungal agents: achievements and challenges","volume":"523","author":"Soliman","year":"2017","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0225","article-title":"Efficacy of an oral lipid nanocrystal (LNC) formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis","volume":"68","author":"Gu","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.892_bib0226","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cid\/ciad440","article-title":"Oral lipid nanocrystal amphotericin B for cryptococcal meningitis: a randomized clinical trial","volume":"77","author":"Boulware","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0227","doi-asserted-by":"crossref","first-page":"ofae346","DOI":"10.1093\/ofid\/ofae346","article-title":"Oral lipid nanocrystal amphotericin B (MAT2203) for the treatment of invasive fungal infections","volume":"11","author":"Dalton","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jtct.2025.01.892_bib0228","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.3389\/fimmu.2017.01939","article-title":"Methods of controlling invasive fungal infections using CD8(+) T cells","volume":"8","author":"Kumaresan","year":"2017","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0229","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1002\/cti2.1249","article-title":"Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant","volume":"10","author":"Gottlieb","year":"2021","journal-title":"Clin Transl Immunol"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0230","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/14653240410006040","article-title":"Generation of Aspergillus- and CMV-specific T-cell responses using autologous fast DC","volume":"6","author":"Ramadan","year":"2004","journal-title":"Cytotherapy"},{"issue":"13","key":"10.1016\/j.jtct.2025.01.892_bib0231","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","article-title":"Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation","volume":"106","author":"Perruccio","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0232","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1038\/s41375-023-02033-5","article-title":"Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study)","volume":"37","author":"Jiang","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0233","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/infdis\/jis308","article-title":"Characterization of the cellular immune responses to Rhizopus oryzae with potential impact on immunotherapeutic strategies in hematopoietic stem cell transplantation","volume":"206","author":"Schmidt","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2025.01.892_bib0234","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.omtm.2018.03.003","article-title":"A new method for reactivating and expanding T cells specific for Rhizopus oryzae","volume":"9","author":"Castillo","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0235","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcyt.2012.11.014","article-title":"Clinical-scale generation of multi-specific anti-fungal T cells targeting Candida, Aspergillus and mucormycetes","volume":"15","author":"Tramsen","year":"2013","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0236","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-gamma in the treatment of intractable mucormycosis","volume":"17","author":"Grimaldi","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0237","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1097\/HS9.0000000000000530","article-title":"Immune checkpoint blockade for aspergillosis and mucormycosis coinfection","volume":"5","author":"Banck","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtct.2025.01.892_bib0238","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mmcr.2022.06.003","article-title":"Nivolumab and interferon-gamma rescue therapy to control mixed mould and bacterial superinfection after necrotizing fasciitis and septic shock","volume":"37","author":"Lukaszewicz","year":"2022","journal-title":"Med Mycol Case Rep"},{"key":"10.1016\/j.jtct.2025.01.892_bib0239","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2022.06.035","article-title":"Nivolumab induces long-term remission in a patient with fusariosis","volume":"173","author":"Khatamzas","year":"2022","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0240","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1128\/AAC.46.7.2234-2237.2002","article-title":"Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum","volume":"46","author":"Gil-Lamaignere","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0241","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1086\/428503","article-title":"Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes","volume":"191","author":"Gil-Lamaignere","year":"2005","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0242","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/13693780412331271072","article-title":"Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp","volume":"43","author":"Gil-Lamaignere","year":"2005","journal-title":"Med Mycol"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.892_bib0243","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1086\/320767","article-title":"Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor","volume":"32","author":"Garcia-Diaz","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0244","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000342121","article-title":"Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease","volume":"129","author":"Safdar","year":"2013","journal-title":"Acta Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0245","doi-asserted-by":"crossref","first-page":"ofac535","DOI":"10.1093\/ofid\/ofac535","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) as adjuvant therapy for invasive fungal diseases","volume":"9","author":"Chen","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"34","key":"10.1016\/j.jtct.2025.01.892_bib0246","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1200\/JCO.2014.60.5121","article-title":"Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV trial","volume":"33","author":"Wan","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.01.892_bib0247","article-title":"Detection of the dimorphic phases of Mucor circinelloides in blood cultures from an immunosuppressed female","volume":"2016","author":"Arroyo","year":"2016","journal-title":"Case Rep Infect Dis"},{"issue":"11-12","key":"10.1016\/j.jtct.2025.01.892_bib0248","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/00365540500262542","article-title":"Central venous catheter-associated fungemia secondary to mucormycosis","volume":"37","author":"Chan-Tack","year":"2005","journal-title":"Scand J Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0249","doi-asserted-by":"crossref","first-page":"146","DOI":"10.7883\/yoken.JJID.2009.146","article-title":"Fungemia and cutaneous zygomycosis due to Mucor circinelloides in an intensive care unit patient: case report and review of literature","volume":"62","author":"Dizbay","year":"2009","journal-title":"Jpn J Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0250","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01409-22","article-title":"A multiplex PCR and DNA-sequencing workflow on serum for the diagnosis and species identification for invasive Aspergillosis and mucormycosis","volume":"61","author":"Imbert","year":"2023","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0251","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/13693780802524506","article-title":"Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases","volume":"47","author":"Rodriguez-Tudela","year":"2009","journal-title":"Med Mycol"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0252","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/13693786.2012.675629","article-title":"Invasive Scopulariopsis brevicaulis infection in an immunocompromised patient and review of prior cases caused by Scopulariopsis and Microascus species","volume":"50","author":"Iwen","year":"2012","journal-title":"Med Mycol"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0253","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.diagmicrobio.2007.04.022","article-title":"Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay","volume":"59","author":"Cummings","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0254","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/jvim.16244","article-title":"Disseminated Rasamsonia argillacea species complex infections in 8 dogs","volume":"35","author":"Dear","year":"2021","journal-title":"J Vet Intern Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0255","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1128\/jcm.35.1.257-260.1997","article-title":"Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan","volume":"35","author":"Swanink","year":"1997","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.jtct.2025.01.892_bib0256","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1128\/CVI.00009-09","article-title":"Detection of (1\u2013>3)-beta-D-glucan as an adjunct to diagnosis in a mixed population with uncommon proven invasive fungal diseases or with an unusual clinical presentation","volume":"16","author":"Cuetara","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0257","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myad045","article-title":"Amphotericin B, itraconazole, posaconazole, and isavuconazole MICs against clinical Mucorales isolates obtained by visual inspection and spectrophotometric reading according to the EUCAST 9.4 procedure","volume":"61","author":"Escribano","year":"2023","journal-title":"Med Mycol"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0258","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0259","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/myc.12222","volume":"57","author":"Abidi","year":"2014","journal-title":"Mycoses"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0260","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1128\/AAC.00286-10","article-title":"International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole","volume":"54","author":"Lortholary","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0261","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1128\/AAC.05910-11","article-title":"Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species","volume":"56","author":"Lackner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0262","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/myc.13067","article-title":"Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: analysis of patients in the FungiScope(R) registry","volume":"63","author":"Jenks","year":"2020","journal-title":"Mycoses"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0263","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/JCM.00793-10","article-title":"Spectrum of clinically relevant Acremonium species in the United States","volume":"49","author":"Perdomo","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0264","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/mmy\/myu047","article-title":"Recognizing filamentous basidiomycetes as agents of human disease: a review","volume":"52","author":"Chowdhary","year":"2014","journal-title":"Med Mycol"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0265","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3947\/ic.2020.0068","article-title":"Pneumonia due to Schizophyllum commune in a patient with acute myeloid leukemia: case report and literature review","volume":"54","author":"Kim","year":"2022","journal-title":"Infect Chemother"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0266","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1128\/AAC.47.7.2339-2341.2003","article-title":"Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents","volume":"47","author":"Cuenca-Estrella","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.892_bib0267","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1128\/JCM.01927-13","article-title":"Scopulariopsis, a poorly known opportunistic fungus: spectrum of species in clinical samples and in vitro responses to antifungal drugs","volume":"51","author":"Sandoval-Denis","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0268","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1128\/AAC.00162-06","article-title":"In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis","volume":"50","author":"Cuenca-Estrella","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0269","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1128\/AAC.00145-15","article-title":"In vitro triple combination of antifungal drugs against clinical Scopulariopsis and Microascus species","volume":"59","author":"Yao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0270","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1128\/AAC.02275-15","article-title":"Virulence and resistance to antifungal therapies of Scopulariopsis species","volume":"60","author":"Paredes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.892_bib0271","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/jac\/dkac235","article-title":"Invasive Trichoderma spp. infections: clinical presentation and outcome of cases from the literature and the FungiScope(R) registry","volume":"77","author":"Sal","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0272","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1086\/597400","article-title":"Phaeohyphomycosis in a tertiary care cancer center","volume":"48","author":"Ben-Ami","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0273","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/jof2010002","article-title":"Phaeohyphomycosis in transplant patients","volume":"2","author":"Revankar","year":"2015","journal-title":"J Fungi (Basel)"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0274","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1086\/338636","article-title":"Disseminated phaeohyphomycosis: review of an emerging mycosis","volume":"34","author":"Revankar","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0275","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1086\/380635","article-title":"Primary central nervous system phaeohyphomycosis: a review of 101 cases","volume":"38","author":"Revankar","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2025.01.892_bib0276","series-title":"AmBisome (Amphotericin B [Liposomal]) [Prescribing Information]","year":"2022"},{"key":"10.1016\/j.jtct.2025.01.892_bib0277","unstructured":"Merck Sharp & Dohme LLC 2022, Cancidas- Prescribing information. Accessed 20 February 2025, https:\/\/www.merck.com\/product\/usa\/pi_circulars\/c\/cancidas\/cancidas_pi.pdf?site_intent=acknowledged."},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0278","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.bbmt.2011.11.029","article-title":"Important drug interactions in hematopoietic stem cell transplantation: what every physician should know","volume":"18","author":"Glotzbecker","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0279","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/sj.bmt.1704316","article-title":"Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know","volume":"33","author":"Leather","year":"2004","journal-title":"Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0280","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/1060028019896894","article-title":"The influence of different triazole antifungal agents on the pharmacokinetics of cyclophosphamide","volume":"54","author":"Cai","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0281","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1080\/10428194.2022.2087067","article-title":"Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study","volume":"63","author":"Kasudhan","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0282","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2003-07-2512","article-title":"Cyclophosphamide metabolism is affected by azole antifungals","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.01.892_bib0283","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100396","article-title":"Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6","volume":"39","author":"Shibata","year":"2021","journal-title":"Drug Metab Pharmacokinet"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0284","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbmt.2007.03.005","article-title":"Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation","volume":"13","author":"Upton","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0285","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults","volume":"6","author":"Groll","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jtct.2025.01.892_bib0286","doi-asserted-by":"crossref","first-page":"66","DOI":"10.12659\/AOT.906164","article-title":"Pharmacokinetic drug-drug interactions between immunosuppressant and anti-infective agents: antimetabolites and corticosteroids","volume":"23","author":"Van Matre","year":"2018","journal-title":"Ann Transplant"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.01.892_bib0287","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1439-0507.2008.01524.x","article-title":"Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity","volume":"51","author":"Christopeit","year":"2008","journal-title":"Mycoses"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0288","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2005.12.032","article-title":"Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Marty","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.01.892_bib0289","unstructured":"Sanofi 2024. Rezurock- Prescribing information. Accessed 20 February 2025, https:\/\/products.sanofi.us\/rezurock\/rezurock.pdf."},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0290","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cpdd.1082","article-title":"A phase 1 pharmacokinetic drug interaction study of belumosudil coadministered with CYP3A4 inhibitors and inducers and proton pump inhibitors","volume":"11","author":"Schueller","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jtct.2025.01.892_bib0291","unstructured":"Abbvie 2024. Imbruvica- Prescribing information. Accessed 20 February 2025, https:\/\/www.rxabbvie.com\/pdf\/imbruvica_pi.pdf."},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0292","doi-asserted-by":"crossref","first-page":"e00156","DOI":"10.1002\/prp2.156","article-title":"Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants","volume":"3","author":"de Jong","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.892_bib0293","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/cts.12716","article-title":"Itraconazole increases ibrutinib exposure 10-fold and reduces interindividual variation-a potentially beneficial drug-drug interaction","volume":"13","author":"Tapaninen","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jtct.2025.01.892_bib0294","unstructured":"Incite Corporation 2023. Jakafi- Prescribing Information. Accessed 20 February 2025, https:\/\/www.jakafi.com\/jakafiprescribing-information."},{"key":"10.1016\/j.jtct.2025.01.892_bib0295","unstructured":"Merck Sharp & Dohme LLC 2024. Prevymis- Prescribing Information. Accessed 20 February 2025, https:\/\/www.merck.com\/product\/usa\/pi_circulars\/p\/prevymis\/prevymis_pi.pdf?site_intent=acknowledged."},{"issue":"4","key":"10.1016\/j.jtct.2025.01.892_bib0296","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41409-020-01093-w","article-title":"Decrease in voriconazole concentration-to-dose ratio after letermovir initiation: a retrospective, observational study","volume":"56","author":"Hikasa","year":"2021","journal-title":"Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.892_bib0297","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/jcph.1094","article-title":"Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects","volume":"58","author":"Marshall","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.892_bib0298","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s12185-021-03105-x","article-title":"Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation","volume":"113","author":"Nakashima","year":"2021","journal-title":"Int J Hematol"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0299","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1128\/AAC.48.11.4306-4314.2004","article-title":"Potential for interactions between caspofungin and nelfinavir or rifampin","volume":"48","author":"Stone","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0300","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2352-3026(21)00232-5","article-title":"Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs","volume":"9","author":"Br\u00fcggemann","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2025.01.892_bib0301","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104258","article-title":"Clinical pharmacokinetics and drug-drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: a clinical perspective","volume":"195","author":"Cheng","year":"2024","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.01.892_bib0302","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00277-020-04186-0","article-title":"Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia","volume":"99","author":"Meg\u00edas-Vericat","year":"2020","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.892_bib0303","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2025.01.892_bib0304","unstructured":"AbbVie 2024. Venclexta- Prescribing Information. Accessed 20 February 2025, https:\/\/www.rxabbvie.com\/pdf\/venclexta.pdf."},{"key":"10.1016\/j.jtct.2025.01.892_bib0305","unstructured":"Celgene Corporation 2022. Vidaza- Product Information. Accessed 20 February 2025, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/050974s034lbl.pdf."},{"key":"10.1016\/j.jtct.2025.01.892_bib0306","unstructured":"Taiho Oncology 2020. Inqovi- Prescribing Information. Accessed on 20 February 2025, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212576s000lbl.pdf."},{"key":"10.1016\/j.jtct.2025.01.892_bib0307","unstructured":"Astella Pharma 2022. Xospata- Prescribing Information. Accessed 20 February 2025, https:\/\/astellas.us\/docs\/xospata.pdf."},{"issue":"15","key":"10.1016\/j.jtct.2025.01.892_bib0308","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.01.892_bib0309","unstructured":"Novartis 2023. Rydapt- Prescribing Information. Accessed 20 February 2025, https:\/\/www.novartis.com\/usen\/ sites\/novartis_us\/files\/rydapt.pdf."},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0310","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.892_bib0311","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00280-022-04448-w","article-title":"Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)","volume":"90","author":"Sechaud","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jtct.2025.01.892_bib0312","unstructured":"Daiichi Sankyo Inc 2024. Vanflyta-Prescribing Information. Accessed 20 February 2025, https:\/\/daiichisankyo.us\/prescribing-information-portlet\/getPIContent?productName=Vanflyta&inline=true."},{"key":"10.1016\/j.jtct.2025.01.892_bib0313","unstructured":"Bayer Pharmaceuticals Corporation 2018. Nexavar- Prescribing Information. Accessed 20 February 2025, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021923s020lbl.pdf."},{"issue":"26","key":"10.1016\/j.jtct.2025.01.892_bib0314","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.892_bib0315","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00280-005-0068-6","article-title":"Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmaco kinetics","volume":"57","author":"Lathia","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jtct.2025.01.892_bib0316","unstructured":"Pfizer Inc 2024. Bosulif- Prescribing Information. Accessed 20 February 2025, https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=884."},{"key":"10.1016\/j.jtct.2025.01.892_bib0317","unstructured":"Bristol-Myers Squibb 2024. Sprycel- Prescribing Information. Accessed 20 February 2025, https:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf."},{"key":"10.1016\/j.jtct.2025.01.892_bib0318","unstructured":"Novartis Pharmaceuticals Corporation 2024. Tasigna- Prescribing Information. Accessed 20 February 2025, https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/tasigna.pdf."},{"key":"10.1016\/j.jtct.2025.01.892_bib0319","unstructured":"Millennium Pharmaceuticals 2024. Iclusig- Prescribing Information. Accessed 20 February 2025, https:\/\/www.iclusig.com\/sites\/default\/files\/2023-02\/iclusig-prescribing-information.pdf."},{"key":"10.1016\/j.jtct.2025.01.892_bib0320","unstructured":"Bristol-Myers Squibb Company 2025. Idhifa- Prescribing Information. Accessed 20 February 2025, https:\/\/packageinserts.bms.com\/pi\/pi_idhifa.pdf."},{"key":"10.1016\/j.jtct.2025.01.892_bib0321","unstructured":"Agios Pharmaceuticals Inc 2023. Tibsovo- Prescribing Information. Accessed 20 February 2025, https:\/\/www.tibsovopro.com\/pdf\/prescribinginformation.pdf."},{"issue":"11","key":"10.1016\/j.jtct.2025.01.892_bib0322","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35251","article-title":"Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"130","author":"Dinh","year":"2024","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.892_bib0323","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1097\/INF.0000000000003659","article-title":"New developments in pediatric antifungal pharmacology","volume":"41","author":"Groll","year":"2022","journal-title":"Pediatr Infect Dis J"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672501005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672501005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:15:24Z","timestamp":1743484524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672501005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":323,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S266663672501005X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.892","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Society of Transplantation and Cellular Therapy Series: #8-Management and Prevention of Non-Aspergillus Molds in Hematopoietic Cell Transplantation Recipients","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}